Prothena Corp Public (PRTA) Net Cash Flow Growth (1y) (2013 - 2026)
Prothena Corp Public (PRTA) Net Cash Flow Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 53.46% |
| 10 | Prothena Corp Public | 469.95 Mn | 140.48 Mn | - | 141.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 141.03% |
| Dec 31, 2025 | 51.31% |
| Sep 30, 2025 | 9.52% |
| Jun 30, 2025 | -385.98% |
| Mar 31, 2025 | 26.09% |
| Dec 31, 2024 | 8.05% |
| Sep 30, 2024 | -480.64% |
| Jun 30, 2024 | 160.06% |
| Mar 31, 2024 | -198.56% |
| Dec 31, 2023 | -124.15% |
| Sep 30, 2023 | 189.51% |
| Jun 30, 2023 | 20.84% |
| Mar 31, 2023 | 32.90% |
| Dec 31, 2022 | 1,126.65% |
| Sep 30, 2022 | -106.62% |
| Jun 30, 2022 | -160.17% |
| Mar 31, 2022 | -175.82% |
| Dec 31, 2021 | -9.71% |
| Sep 30, 2021 | 1,124.44% |
| Jun 30, 2021 | 403.25% |